Earlier this month the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) announced the purchase of two additional medical countermeasures (MCMs) to treat bone marrow injuries of radiological incident victims. These products are Neulasta and Leukine; both colony stimulating factors which can be used to help reduce the risk of infection and death for those with acute radiation syndrome.

The purchase of these products will increase the available supply of MCMs for radiological threats in the Strategic National Stockpile (SNS) and also will enhance response operational capacity as Neulasta treatments only need to be provided once per week compared to older treatments such as Neupogen which must be given once daily. Click to view the full press release for more information.